Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 215, Issue 1, Pages 52-55Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiw501
Keywords
West Nile virus; vaccine; flavivirus
Categories
Funding
- National Institute of Allergy and Infectious Disease Intramural Research Program, National Institutes of Health [HHSN272200900010C]
Ask authors/readers for more resources
West Nile virus (WNV) is a major cause of mosquito-borne illness in the United States. Human disease ranges from mild febrile illness to severe fatal neurologic infection. Adults aged > 60 years are more susceptible to neuroinvasive disease accompanied by a high mortality rate or long-lasting neurologic sequelae. A chimeric live attenuated West Nile virus vaccine, rWN/DEN4 Delta 30, was shown to be safe and immunogenic in healthy adults aged 18-50 years. This study evaluated rWN/DEN4 Delta 30 in flavivirus-naive adults aged 50-65 years and found it to be safe and immunogenic. Outbreaks of WNV infection tend to be unpredictable, and a safe and effective vaccine will be an important public health tool.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available